Lineage Cell Therapeutics (LCTX) Gross Profit (2011 - 2026)

Lineage Cell Therapeutics has reported Gross Profit for 16 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 17.67% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $14.7 million (up 57.99% YoY), and the FY2025 full-year result was $14.4 million, up 57.23% from the prior year.
• Gross Profit for Q1 2026 stood at $1.7 million, down from $6.5 million in the prior quarter.
• The five-year high for Gross Profit was $6.5 million in Q4 2025, with the low at $1.1 million in Q3 2023.
• Historically, Gross Profit has averaged $2.8 million across 5 years, with a median of $2.7 million in 2024.
• Annual changes were most pronounced in 2022 — Gross Profit soared 1713.98% — and 2023, when it sank 61.02%.
• Lineage Cell Therapeutics' Gross Profit stood at $1.8 million in 2022, then gained by 1.05% to $1.8 million in 2023, then jumped by 48.14% to $2.7 million in 2024, then jumped by 141.05% to $6.5 million in 2025, then plunged by 73.63% to $1.7 million in 2026.
• The last three Gross Profit figures came in at $1.7 million (Q1 2026), $6.5 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.